OLMEKAR HCT 20/5/12.5 olmesartan medoxomil/amlodipine (as besilate) and hydrochlorothiazide 20 mg/5 mg/12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

olmekar hct 20/5/12.5 olmesartan medoxomil/amlodipine (as besilate) and hydrochlorothiazide 20 mg/5 mg/12.5 mg tablet blister pack

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg); hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - it is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination.this fixed dose combination is not indicated for initial therapy.

OLMEKAR HCT 40/10/12.5 olmesartan medoxomil/amlodipine (as besilate) and hydrochlorothiazide 40 mg/10 mg/12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

olmekar hct 40/10/12.5 olmesartan medoxomil/amlodipine (as besilate) and hydrochlorothiazide 40 mg/10 mg/12.5 mg tablet blister pack

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - it is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination.this fixed dose combination is not indicated for initial therapy.

OLMEKAR HCT 40/5/25 Olmesartan medoxomil, Amlodipine (as besilate) and Hydrochlorothiazide 40 mg/5 mg/25 mg tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

olmekar hct 40/5/25 olmesartan medoxomil, amlodipine (as besilate) and hydrochlorothiazide 40 mg/5 mg/25 mg tablets blister pack

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg); hydrochlorothiazide, quantity: 25 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - it is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination.this fixed dose combination is not indicated for initial therapy.

OLMEKAR HCT 40/5/12.5 olmesartan medoxomil/amlodipine (as besilate) and hydrochlorothiazide 40 mg/5 mg/12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

olmekar hct 40/5/12.5 olmesartan medoxomil/amlodipine (as besilate) and hydrochlorothiazide 40 mg/5 mg/12.5 mg tablet blister pack

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg); hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; pregelatinised maize starch; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - it is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination.this fixed dose combination is not indicated for initial therapy.

OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE TEVA 20/25.0 Milligram Film Coated Tablet Ireland - English - HPRA (Health Products Regulatory Authority)

olmesartan medoxomil/hydrochlorothiazide teva 20/25.0 milligram film coated tablet

teva pharma b.v. - olmesartan medoxomil, hydrocholothiazide - film coated tablet - 20/25.0 milligram - angiotensin ii antagonists and diuretics

ARW OLMESARTAN HCTZ 20/12.5 olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg film coated tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

arw olmesartan hctz 20/12.5 olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg film coated tablets blister pack

arrotex pharmaceuticals pty ltd - olmesartan medoxomil, quantity: 20 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: hypromellose; purified water; hyprolose; lactose monohydrate; magnesium stearate; microcrystalline cellulose; titanium dioxide; iron oxide yellow; macrogol 4000 - indicated for the treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

ARW OLMESARTAN HCTZ 40/25 olmesartan medoxomil/hydrochlorothiazide 40/25 mg film coated tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

arw olmesartan hctz 40/25 olmesartan medoxomil/hydrochlorothiazide 40/25 mg film coated tablets blister pack

arrotex pharmaceuticals pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hypromellose; purified water; microcrystalline cellulose; hyprolose; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 4000 - indicated for the treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

ARW OLMESARTAN HCTZ 40/12.5 olmesartan medoxomil/hydrochlorothiazide 40/12.5 mg film coated tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

arw olmesartan hctz 40/12.5 olmesartan medoxomil/hydrochlorothiazide 40/12.5 mg film coated tablets blister pack

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; hyprolose; purified water; microcrystalline cellulose; hypromellose; titanium dioxide; iron oxide yellow; macrogol 4000 - indicated for the treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

OLMESARTAN MEDOXOMIL / HYDROCHLOROTHIAZIDE TABLET Canada - English - Health Canada

olmesartan medoxomil / hydrochlorothiazide tablet

jubilant generics limited - hydrochlorothiazide; olmesartan medoxomil - tablet - 25mg; 40mg - hydrochlorothiazide 25mg; olmesartan medoxomil 40mg - angiotensin ii receptor antagonists

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE- olmesartan medoxomil and hydrochlorothiazide 20/12.5 tablet OLMESARTAN MEDOXOMIL United States - English - NLM (National Library of Medicine)

olmesartan medoxomil and hydrochlorothiazide- olmesartan medoxomil and hydrochlorothiazide 20/12.5 tablet olmesartan medoxomil

torrent pharmaceuticals limited - olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - olmesartan medoxomil 20 mg - olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see dosage and administration (2)] . lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals